Search results for: Histamine
#39508246 2024/11/06 To Up
The association between metabolite profiles and impaired bone microstructure in adult growth hormone deficient rats.
Adult growth hormone deficiency (AGHD) is associated with an increased risk of fractures and impaired bone microstructure. Understanding the metabolic changes accompanying bone deterioration in AGHD might provide insights into mechanisms behind molecular changes and develop new biomarkers or nutritional strategies for bone destruction. Our study aimed to investigate the association between altered metabolite patterns and impaired bone microstructure in adult rats with growth hormone deficiency.Xiaonan Guo, Shanshan Liu, Wenjing Hu, Xiaorui Lyu, Hanyuan Xu, Huijuan Zhu, Hui Pan, Linjie Wang, Yu Wan, Hongbo Yang, Fengying Gong
2642 related Products with: The association between metabolite profiles and impaired bone microstructure in adult growth hormone deficient rats.
96/kit100 μg20ug100.00 ug1 mg50 μgProtein96 tests96 wells (1 kit)Related Pathways
#39504861 2024/11/02 To Up
Ion-exchange chromatography in the assessment of environmental pollution with chlortetracycline.
Chemical substances such as drugs pose a threat to the environment. One of the substances recorded in soil and water is chlortetracycline, an antibiotic used in veterinary medicine. Plants exposed to such xenobiotics show changes in the content of biogenic amines. An analytical technique - ion exchange chromatography is used to assess their content. The occurrence of these active compounds is used to determine the degree of environmental pollution with chemical substances. The study aimed to evaluate the toxicity of chlortetracycline (CTC) at concentrations of 0; 0.05; 0.1; 0.2 0.5;1; 2; 3; and 5 mM towards the test organism Lemna minor, and determine the content of biogenic amines in the plant tissues. The content of biogenic amines was analyzed by ion-exchange chromatography with post-column ninhydrin derivatization and photometric detection. The Lemna test proved that increasing concentrations of CTC had a toxic effect on the plants. It was calculated that the Lowest Observed Effects Concentration (LOEC) of CTC at >0.04 mM and >0.05 mM was phytotoxic to L. minor growth and yield. It was determined that the levels of histamine, tyramine, and cadaverine exhibited an increase, reaching 1.04, 1.90, and 3.10 µg g of tissue at 2.00 mM CTC. Simultaneously, spermine and putrescine increased to 1.21 and 3.89 µg g of tissue at concentrations of 0.10 and 0.50 mM of the drug. Conversely, the study revealed an over 88 % reduction in spermidine in plants at 5 mM of CTC. Using ion-exchange chromatography, analysis of biogenic amines, particularly spermidine and cadaverine, highlighted these intra-tissue compounds as sensitive biomarkers for water contamination with the tested drug. This research confirmed that the Lemna test is effective for assessing CTC toxicity and that ion-exchange chromatography is useful for evaluating environmental pollution by this antibiotic.Łukasz Sikorski, Agnieszka Bęś, Elżbieta Karetko-Sikorska, Wojciech Truszkowski, Katarzyna Tomaszewska
2401 related Products with: Ion-exchange chromatography in the assessment of environmental pollution with chlortetracycline.
1100 μgRelated Pathways
#39504659 2024/11/04 To Up
Neuropeptide FF prevented histamine- or chloroquine-induced acute itch behavior through non-NPFF receptors mechanism in male mice.
The neuropeptide FF (NPFF) system regulates various physiological and pharmacological functions, particularly pain modulation. However, the modulatory effect of NPFF system on itch remains unclear. To investigate the modulatory effect and functional mechanism induced by NPFF system on acute itch, we examined the effects of supraspinal administration of NPFF and related peptides on acute itch induced by intradermal (i.d.) injection of histamine or chloroquine in male mice. Our results indicated that intracerebroventricular (i.c.v.) administration of NPFF dose-dependently prevented histamine- or chloroquine-induced acute itch behaviors. In addition, the modulatory effect of NPFF was not affected by the selective NPFF receptor antagonist RF9. Furthermore, we investigated the effects of NPVF and dNPA, the selective agonists of NPFF and NPFF receptors respectively, on the acute itch. The results demonstrated that both NPFF agonists effectively prevented acute itch induced by histamine or chloroquine in a manner similar to NPFF, and their effects were also not modified by RF9. To further investigate the possible mechanism of the NPFF receptors agonists, the NPFF-derived analogues [Phg]-NPFF and NPFF(1-7)-NH that could not activate NPFF receptors in cAMP assays were subsequently tested in the acute itch model. Interestingly, [Phg]-NPFF, but not NPFF(1-7)-NH, prevented acute itch behavior after i.c.v. administration. In conclusion, our findings reveal that NPFF and related peptides prevent histamine- and chloroquine-induced acute itch through a NPFF receptor-independent mechanism. And it was revealed that the C-terminal phenyl structure of NPFF may play a crucial role in these modulatory effects on acute itch.Honghai Tang, Ting Zhang, Jiamin Feng, Mengna Zhang, Biao Xu, Qinqin Zhang, Ning Li, Nan Zhang, Quan Fang
2790 related Products with: Neuropeptide FF prevented histamine- or chloroquine-induced acute itch behavior through non-NPFF receptors mechanism in male mice.
100 ug10mg10mg20mg100 μg10mg10mg5mgRelated Pathways
#39504585 2024/10/30 To Up
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Narcolepsy is a rare, chronic neurological disorder characterized by a dysregulated sleep-wake cycle, with core clinical features including excessive daytime sleepiness (EDS), cataplexy, hypnopompic/hypnagogic hallucinations, and sleep paralysis. Several treatment options are available for the symptomatic management of narcolepsy, but they have limitations. Comorbidities of narcolepsy further limit the treatment choices. Blocking of histamine 3 (H3) receptors has been demonstrated to be a viable approach for the management of symptoms of narcolepsy. Samelisant (SUVN-G3031) is a new H3 receptor inverse agonist. The efficacy, safety, tolerability, and pharmacokinetics of Samelisant in narcolepsy patients were evaluated in a phase 2, double-blind, placebo-controlled study (ClinicalTrials.gov identifier: NCT04072380). Patients diagnosed with narcolepsy according to the International Classification of Sleep Disorders criteria and having an Epworth Sleepiness Scale (ESS) score of ≥12 and a mean Maintenance of Wakefulness Test (MWT) time of <12 min across the 4 sessions at baseline were enrolled. The total study duration was up to 7 weeks, which included a screening period of 4 weeks, a treatment period of 2 weeks, and a safety follow-up 1 week after the last study drug administration. The primary efficacy measure was the change in total ESS score compared to placebo. Secondary and exploratory assessments included the Clinical Global Impression of Severity, MWT, Clinical Global Impression of Change, Patient Global Impression of Change and cataplexy rate. Safety assessments included monitoring adverse events (AEs) and laboratory assessments. Of the 426 patients screened, 190 were randomized. The safety and intention-to-treat population included 188 and 164 patients, respectively. A statistically significant treatment effect of Samelisant was observed on the primary endpoint, indicating improvements in EDS. The treatment's impact on EDS was also evident on the other patients' and clinicians' perspectives scales. The AEs reported in ≥5 % patients in any treatment groups were insomnia, abnormal dreams, nausea, and hot flush. Global phase 3 studies and long-term safety and efficacy assessments of Samelisant are planned to reaffirm the current findings.Ramakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, Jyothsna Ravula, Vijay Benade, Satish Jetta, Santosh Kumar Pandey, Ramkumar Subramanian, Veera Raghava Chowdary Palacharla, Abdul Rasheed Mohammed, Renny Abraham, Dhanunjay Kumar Dogiparti, Ilayaraja Kalaikadhiban, Pradeep Jayarajan, Venkat Jasti, Richard K Bogan
1554 related Products with: Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
200ul1100 μgRelated Pathways
#39503620 2024/11/06 To Up
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.
Gastroesophageal reflux disease (GERD) is a common debilitating chronic disease presenting in two main forms based on esophageal mucosal appearance, the erosive reflux disease (ERD) and the non-erosive reflux disease (NERD). Acid secretion is a key factor in the disease pathogenesis and management. Potent acid-suppressant drugs have been manufactured since the mid of 1970s, initially with histamine-H2-receptors antagonists, and later, inhibitors of the proton pump (H+-K+-ATPase). More recently, potassium-competitive acid blockers (P-CABs), particularly Vonoprazan, have been introduced. Vonoprazan has shown high efficacy and safety profiles and exhibits several advantages that allow to overcome shortcomings of proton pump inhibitors (PPIs).Elisa Marabotto, Francesco Calabrese, Andrea Pasta, Pierfrancesco Visaggi, Nicola de Bortoli, Amir Mari, Salvatore Tolone, Matteo Ghisa, Luisa Bertin, Vincenzo Savarino, Edoardo Vincenzo Savarino
2942 related Products with: Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.
250 mg 1 G 1 G1 5 GRelated Pathways
#39503414 2024/11/06 To Up
Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings.
Cancer remains a major global cause of death, posing significant treatment challenges. The interactions between tumor cells and the tumor microenvironment (TME) are crucial in influencing tumor initiation, progression, metastasis, and treatment response. There has been significant research and clinical interest in targeting the TME as a therapeutic approach in cancer, with advancements being made through drug development. Histamine binds to HRH1 receptors on the TME, which inhibit CD8+ T cell activity, promote tumor growth, and contribute to resistance against immunotherapy. By inhibiting CD8+ T cells, the effectiveness of immunotherapies targeting these cells is reduced. By blocking the HRH1 pathway, H1-antihistamines can mitigate this suppression and enhance the response to immunotherapies that target CD8+ T cells. Therefore, understanding the role of histamine and its potential impact on T cells and the role of H1-antihistamines in improving immune-oncology (I/O) agents' efficacy ultimately could lead to more effective cancer therapies. The objective of this review is to examine the current literature to investigate the potential role of H1-antihistamines on the effectiveness of I/O drugs and their role in enhancing treatment against cancer. We conducted a comprehensive literature search, which included multiple databases including PubMed, Google Scholar, and EMBASE, as well as a search of oncology congresses. Our literature review initially identified thirty studies. Twenty-three of these were excluded for failing to meet inclusion criteria, which varied from study design to the type of antihistamines and patient populations involved. The clinical studies investigated the effect of different generations of H1-antihistamines in combination with I/O treatments on patients' outcomes. The findings from these studies indicated that patients using H1-antihistamines concomitantly with I/O agents experienced longer median overall survival (mOS), progression-free survival (mPFS), or improved survival compared to those who did not use antihistamines. Additionally, these trials differentiated between cationic and non-cationic H1-antihistamines, revealing that users of cationic antihistamines had overal better outcomes in terms of longer mOS and mPFS. The assessed trials were consistent in their comparisons of quantitative and qualitative, efficacy, and safety outcomes.Oday Hamid, Negar Hamidi
2867 related Products with: Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings.
Related Pathways
#39502691 2024/10/21 To Up
Histamine and Th2 cytokines independently and synergistically upregulate MMP12 expression in human M2 macrophages.
Beyond Th2 cells and various immune cells, M2 macrophages have been identified in lesional skin of atopic dermatitis (AD) indicating their involvement in the disease's underlying mechanisms. MMP12, a matrix-degrading enzyme, which is predominantly produced by macrophages, is increased in skin lesions of AD patients. In this study we investigated the expression of MMP12 mRNA in lesional AD skin at single cell level through RNA sequencing (scRNA-seq) and the expression of MMP12 in M2 macrophages from healthy individuals and AD patients in response to Th2 cytokines and histamine using quantitative PCR and ELISA. Additionally, we analyzed macrophages from dupilumab-treated AD patients using the same methods to assess the influence of Th2 cytokines on MMP12 expression . ScRNA-seq identified macrophages as the primary producers of MMP12 in lesional AD skin. , both MMP12 mRNA and protein expression were significantly increased in monocytes during differentiation to M2 macrophages in the presence of histamine, of Th2 cytokines or of Th2 cytokines in combination with histamine. In M2 macrophages obtained from dupilumab-treated AD patients, the upregulation of MMP12 expression by IL-4 and IL-13 was attenuated. Our findings unveil a novel mechanism whereby Th2 cytokines and histamine regulate MMP12 expression, potentially impacting skin barrier homeostasis in AD.Alice Pereira da Fonseca, Stephan Traidl, Ralf Gutzmer, Katrin Schaper-Gerhardt, Thomas Werfel, Susanne Mommert
1578 related Products with: Histamine and Th2 cytokines independently and synergistically upregulate MMP12 expression in human M2 macrophages.
1000 0.1 mg16 Arrays/Slide100 1 ml16 Arrays/Slide100 μg16 Arrays/Slide200 100ul100 μgRelated Pathways
#39497323 2024/11/04 To Up
Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.
Cetirizine is an antihistamine commonly used to treat allergic rhinitis and other allergic conditions. Cetirizine is often prescribed to breastfeeding mothers although there is limited information on infant exposure via breast milk. The aim of this study was to develop a popPK model based on data from a lactation study to predict cetirizine breast milk concentrations and estimate the relative infant dose (RID) in a breastfed infant. A popPK model was developed in NONMEM on data from a human lactation study including 35 women using cetirizine or levocetirizine while breastfeeding. Serial samples of breast milk were collected (n = 205) and the cetirizine concentrations quantified using a validated LC-MS/MS method. A one-compartment model of cetirizine in breast milk was developed and employed to calculate the relative infant dose (RID). Covariates related to the maternal characteristics and breastfeeding patterns were evaluated in the model; only milk sampling pumping duration was found to be a significant covariate, with an increasing pumping duration leading to an increased apparent milk volume of distribution (V). The mean RID was 1.99% with the highest RID being 3.36% at C. PopPK modelling could be used to estimate infant exposure to cetirizine via breast milk. The low predicted exposure in infants supports that cetirizine is compatible with breastfeeding.Erik Melander, Elisabet I Nielsen, Annika Lindqvist, Markus Hovd, Peggy Gandia, Alice Panchaud, Monia Guidi, Pieter Annaert, Pawel Baranczewski, Olav Spigset, Hedvig Nordeng
2672 related Products with: Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.
100 μg100 μg100 μg100 μg100 μg1 mg100 100 μgRelated Pathways
#39495351 2024/11/04 To Up
Sea Buckthorn Flavonoid Extracted with High Hydrostatic Pressure Alleviated Shrimp Allergy in Mice through the Microbiota and Metabolism.
Sea buckthorn ( L.) known as the deciduous shrub has been reported to have effects of antioxidant, anti-inflammatory, and immunomodulatory activities. Tropomyosin (TM) induced a regulatory immune response associated with food allergy. In this study, a mouse model of food allergy sensitized to tropomyosin (TM) was established to assess the antiallergic properties of sea buckthorn flavonoid extract (SBF). SBF alleviated mice's allergic symptoms and exhibited a significant reduction in the levels of IgE and histamine. Meanwhile, SBF repaired the allergic Th2 cell overpolarization generated by TM, via downregulating the IL-4 production and upregulating IFN-γ production to restore the balance of Th1/Th2 cells. Furthermore, the 16S RNA analysis showed that SBF primarily restored the gut microbiota via increasing the abundance in and decreasing in , and . Gut metabolomes determined by liquid chromatography-mass spectrometry (LC-MS) suggested that TM upregulated PE (14:0/22:1(13Z)) and SBF decreased formimino-l-glutamic acid and urocanic acid levels. According to the KEGG pathway analysis, SBF treatment has been shown to modulate glycerophospholipid and histidine metabolism to improve allergic reactions. SBF holds great promise as a novel potential agent for the treatment of food allergies.Xiaoping Feng, Zhuomin Yan, Xiaojing Ren, Yining Jia, Jiao Sun, Jing Guo, Zhenpeng Gao, Huzhong Li, Fangyu Long
2853 related Products with: Sea Buckthorn Flavonoid Extracted with High Hydrostatic Pressure Alleviated Shrimp Allergy in Mice through the Microbiota and Metabolism.
4 Membranes/Box2 Pieces/Box4 Membranes/Box4 Arrays/Slide4 Arrays/Slide2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/SlideRelated Pathways
#39493768 2024/10/18 To Up
Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders.
Because MRGPRX2 is now recognized as the mast cell receptor for basic secretagogues, there is currently a tremendous interest in whether MRGRPX2 could play an important role in various pruritic dermatoses such as chronic spontaneous urticaria. Therefore, we sought to identify new potent and selective antagonists to pharmacologically characterize the biological role of MRGPRX2.Colin H Macphee, Xinzhong Dong, Qi Peng, Daniel V Paone, Per Stahl Skov, Katrine Baumann, Theresa Roethke, Deborah A Goldspink, Samuel K Pearson, Zining Wu
1684 related Products with: Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders.
2 Pieces/Box100 μg8 inhibitors100ug100ug96 assaysRelated Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]